ZymoGenetics, Inc. and Bristol-Myers Squibb Company to Present PEG-Interferon Lambda Phase 2a Interim Clinical Trial Results at AASLD 2010

Published: Oct 04, 2010

SEATTLE & PRINCETON, N.J.--(BUSINESS WIRE)--ZymoGenetics, Inc. (NASDAQ: ZGEN) and Bristol-Myers Squibb Company (NYSE: BMY) announced that interim results from Phase 2a of the EMERGE clinical trial of PEG-Interferon lambda administered with ribavirin in treatment-naïve hepatitis C virus patients, will be presented at the American Association for the Study of Liver Diseases (AASLD) annual meeting in Boston, October 29 – November 2, 2010. PEG-Interferon lambda abstracts, including clinical, pharmacokinetic and viral kinetic data along with in vitro data in combination with direct-acting antiviral agents, were published today and are available on the AASLD website at www.aasld.org.

Back to news